Clinical and molecular predictors of long-term response in HER2 positive metastatic breast cancer patients

Omarini, Claudia; Bettelli, Stefania; Caprera, Cecilia; Manfredini, Samantha; Caggia, Federica; Guaitoli, Giorgia; Moscetti, Luca; Toss, Angela; Cortesi, Laura; Kaleci, Shaniko; Maiorana, Antonino; Cascinu, Stefano; Conte, Pier Franco; Piacentini, Federico

doi:10.1080/15384047.2018.1480287

Cited by 25 publications

(12 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…IL20RB, a receptor of the IL20 subfamily, is involved in both amplified inflammatory and anti-inflammatory responses. Dysregulated expression of IL20RB has been observed in various studies, including the present study [ 57–59 ]. Overexpression of IL20RB was correlated with poor outcome in patients with papillary renal cell carcinoma, the ability of papillary renal cell carcinoma cells to invade and metastasize could be inhibited by silencing IL20RB in vivo [ 60 ].…”

Section: Discussionsupporting

confidence: 70%

Construction of a five-gene prognostic model based on immune-related genes for the prediction of survival in pancreatic cancer

Liu

et al. 2021

Bioscience Reports

View full text Add to dashboard Cite

Purpose: To identify differentially expressed immune-related genes (DEIRGs) and construct a model with survival-related DEIRGs for evaluating the prognosis of patients with pancreatic cancer (PC). Methods: Six microarray gene expression datasets of PC from the Gene Expression Omnibus (GEO) and ImmPort were used to identify DEIRGs. RNA sequencing and clinical data from The Cancer Genome Atlas Program-Pancreatic Adenocarcinoma (TCGA-PAAD) database were used to establish the prognostic model. Univariate, least absolute shrinkage and selection operator (LASSO) and multivariate Cox regression analyses were applied to determine the final variables of the prognostic model. The median risk score was used as the cut-off value to classify samples into low- and high-risk groups. The prognostic model was further validated using an internal validation set of TCGA and an external validation set of GSE62452. Results: In total, 142 DEIRGs were identified from six GEO datasets, 47 were survival-related DEIRGs. A prognostic model comprising five genes (i.e., ERAP2, CXCL9, AREG, DKK1, and IL20RB) was established. High-risk patients had poor survival compared with low-risk patients. The 1-, 2-, 3-year area under the receiver operating characteristic curve of the model reached 0.85, 0.87, and 0.93, respectively. Additionally, the prognostic model reflected the infiltration of neutrophils and dendritic cells. The expression of most characteristic immune checkpoints was significantly higher in the high-risk group versus the low-risk group. Conclusions: The five-gene prognostic model showed reliably predictive accuracy. This model may provide useful information for immunotherapy and facilitate personalized monitoring for patients with PC.

show abstract

Section: Discussionsupporting

confidence: 70%

Construction of a five-gene prognostic model based on immune-related genes for the prediction of survival in pancreatic cancer

Liu

et al. 2021

Bioscience Reports

View full text Add to dashboard Cite

show abstract

“…IL20RB may affect the IL20 signaling pathway and may be involved in the pathogenesis of glaucoma 5 , vitiligo 6 , and psoriasis 7 . Meanwhile, multiple studies have also reported that IL20RB carries a big weight in various cancers, for instance non-small-cell lung cancer (NSCLC) 8 , nasopharyngeal carcinoma (NPC) 9 , breast cancer (BC) 10 , and pancreatic ductal adenocarcinoma (PDAC) 11 . Based on the above research, IL20RB plays an important role in many cancers, but the function of IL20RB in PRCC has not been described.…”

Section: Introductionmentioning

confidence: 99%

Overexpression of interleukin-20 receptor subunit beta (IL20RB) correlates with cell proliferation, invasion and migration enhancement and poor prognosis in papillary renal cell carcinoma

Cui

Leng

2019

J Toxicol Pathol

View full text Add to dashboard Cite

Papillary renal cell carcinoma (PRCC) accounts for about 10 percent of all renal cell carcinomas, and the prognosis is poor for people with advanced disease. Interleukin-20 receptor subunit beta (IL20RB) is a single-pass type I membrane protein of the type II cytokine receptor family and is related to the pathogenesis of chronic inflammation and autoimmune diseases, including psoriasis, glaucoma, vitiligo, rheumatoid arthritis, and inflammatory bowel disease. However, little has been reported on IL20RB with respect to cancer, especially in PRCC. Thus, we performed this study to explore its biological characteristics in PRCC. Data from the TCGA database were used to analyze the expression and prognosis of IL20RB. qRT-PCR was used to detect the expression of IL20RB in PRCC cells in vitro. After knockdown of IL20RB with small interfering RNA (siRNA) technology, the proliferation, migration, and invasion of Ketr-3 cells and the expression of related proteins in the epithelial-mesenchymal transition (EMT) pathway were measured with Cell Counting Kit-8 (CCK-8), transwell, and western blot assays. The findings demonstrated that the expression of IL20RB was upregulated in both PRCC tissues and cells and that the high expression of IL20RB led to low overall survival (OS). Furthermore, after knockdown of IL20RB in vitro, the proliferation, migration, and invasion of Ketr-3 cells were reduced, and the expression of related proteins in the EMT pathway declined, suggesting that IL20RB plays a vital role in PRCC through the EMT pathway. These results reveal the biological significance of IL20RB in PRCC and provide new insight for future targeted drugs.

show abstract

“…Additionally, triple negative breast cancers (TNBC), where there is an absence of ER, PR, and HRE2, account for 10–15% of all breast cancer cases. Compared with other breast cancer subtypes, TNBC is characterized by early relapse and aggressive behavior, with HER2-positive metastatic breast cancer specifically considered an incurable disease with the worst prognosis (Omarini et al, 2018).…”

Section: Introductionmentioning

confidence: 99%

Prognostic factors and survival outcomes according to tumor subtype in patients with breast cancer lung metastases

Chen

Yang

Liu

et al. 2019

PeerJ

View full text Add to dashboard Cite

BackgroundReports on the incidence and prognoses of lung metastases when diagnosing breast cancer patients with different subtypes are limited. Our study investigated the effect of molecular sub-typing stratification on the prognoses of lung metastatic breast caner patients.MethodsPatients with breast cancer and lung metastases were identified from Surveillance, Epidemiology and End Results population-based data between 2010 and 2015. Univariate and multivariate Cox regression analyses were performed to identify risk factors and prognoses, overall survival (OS) and breast cancer-specific survival for patients with breast cancer lung metastases.ResultsWe identified 6,516 patients with lung metastatic breast cancer, representing 1.7% of the entire cohort and 30.4% of the subset with metastatic disease. This included 2,940 hormone receptor (HR)+/HER2− patients, 852 HR+/HER2+ patients, 547 HR−/HER2+ patients and 983 triple-negative patients. The median OS for all lung metastatic patients was 13 months. Multivariate analysis revealed that those lung metastatic breast cancer patients of older age (>80), black race, with poorly differentiated tumors, carcinoma histology, triple-negative subtype, more metastatic sites and no surgery, and no chemotherapy showed significantly poor survival, both overall and breast cancer-specific.ConclusionsOur findings show that molecular sub-type and more metastatic sites might have significant influence on the incidence and prognosis of breast cancer lung metastases. We also identified several prognostic factors that could guide therapy selection in the treatment of lung metastatic patients.

show abstract

Clinical and molecular predictors of long-term response in HER2 positive metastatic breast cancer patients

Abstract: BC: breast cancer; MBC: metastatic breast cancer; LR: long responder; EP: early progressor; FFPE: formalin-fixed paraffin-embedded; CNS: central nervous system; PFS: progression free survival; OS: overall survival.

Cited by 25 publications

References 30 publications

Construction of a five-gene prognostic model based on immune-related genes for the prediction of survival in pancreatic cancer

Construction of a five-gene prognostic model based on immune-related genes for the prediction of survival in pancreatic cancer

Overexpression of interleukin-20 receptor subunit beta (IL20RB) correlates with cell proliferation, invasion and migration enhancement and poor prognosis in papillary renal cell carcinoma

Prognostic factors and survival outcomes according to tumor subtype in patients with breast cancer lung metastases

Contact Info

Product

Resources

About